Aronora is a translational biotechnology company engaged in the early-stage commercial development of proprietary biologic therapeutics, including recombinant monoclonal antibodies and enzymes. Building on the company’s ground-breaking rational approaches to superior drug safety, Aronora’s product candidates have the potential to become first-in-class medical emergency therapeutics to treat life-threatening acute thrombotic vascular diseases early, in the field, even before the patient is hospitalized and the diagnosis is verified.
